Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model
Background Recent clinical trials have demonstrated the possible pleiotropic effects of SGLT2 (sodium-glucose cotransporter 2) inhibitors in clinical cardiovascular diseases. Atrial electrical and structural remodeling is important as an atrial fibrillation (AF) substrate. Methods and Results The pr...
Saved in:
Published in | Journal of the American Heart Association Vol. 10; no. 2; p. e017483 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
John Wiley and Sons Inc
19.01.2021
Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background Recent clinical trials have demonstrated the possible pleiotropic effects of SGLT2 (sodium-glucose cotransporter 2) inhibitors in clinical cardiovascular diseases. Atrial electrical and structural remodeling is important as an atrial fibrillation (AF) substrate. Methods and Results The present study assessed the effect of canagliflozin (CAN), an SGLT2 inhibitor, on atrial remodeling in a canine AF model. The study included 12 beagle dogs, with 10 receiving continuous rapid atrial pacing and 2 acting as the nonpacing group. The 10 dogs that received continuous rapid atrial pacing for 3 weeks were subdivided as follows: pacing control group (n=5) and pacing+CAN (3 mg/kg per day) group (n=5). The atrial effective refractory period, conduction velocity, and AF inducibility were evaluated weekly through atrial epicardial wires. After the protocol, atrial tissues were sampled for histological examination. The degree of reactive oxygen species expression was evaluated by dihydroethidium staining. The atrial effective refractory period reduction was smaller (
=0.06) and the degree of conduction velocity decrease was smaller in the pacing+CAN group compared with the pacing control group (
=0.009). The AF inducibility gradually increased in the pacing control group, but such an increase was suppressed in the pacing+CAN group (
=0.011). The pacing control group exhibited interstitial fibrosis and enhanced oxidative stress, which were suppressed in the pacing+CAN group. Conclusions CAN and possibly other SGLT2 inhibitors might be useful for preventing AF and suppressing the promotion of atrial remodeling as an AF substrate. |
---|---|
AbstractList | Background Recent clinical trials have demonstrated the possible pleiotropic effects of SGLT2 (sodium-glucose cotransporter 2) inhibitors in clinical cardiovascular diseases. Atrial electrical and structural remodeling is important as an atrial fibrillation (AF) substrate. Methods and Results The present study assessed the effect of canagliflozin (CAN), an SGLT2 inhibitor, on atrial remodeling in a canine AF model. The study included 12 beagle dogs, with 10 receiving continuous rapid atrial pacing and 2 acting as the nonpacing group. The 10 dogs that received continuous rapid atrial pacing for 3 weeks were subdivided as follows: pacing control group (n=5) and pacing+CAN (3 mg/kg per day) group (n=5). The atrial effective refractory period, conduction velocity, and AF inducibility were evaluated weekly through atrial epicardial wires. After the protocol, atrial tissues were sampled for histological examination. The degree of reactive oxygen species expression was evaluated by dihydroethidium staining. The atrial effective refractory period reduction was smaller (P=0.06) and the degree of conduction velocity decrease was smaller in the pacing+CAN group compared with the pacing control group (P=0.009). The AF inducibility gradually increased in the pacing control group, but such an increase was suppressed in the pacing+CAN group (P=0.011). The pacing control group exhibited interstitial fibrosis and enhanced oxidative stress, which were suppressed in the pacing+CAN group. Conclusions CAN and possibly other SGLT2 inhibitors might be useful for preventing AF and suppressing the promotion of atrial remodeling as an AF substrate.Background Recent clinical trials have demonstrated the possible pleiotropic effects of SGLT2 (sodium-glucose cotransporter 2) inhibitors in clinical cardiovascular diseases. Atrial electrical and structural remodeling is important as an atrial fibrillation (AF) substrate. Methods and Results The present study assessed the effect of canagliflozin (CAN), an SGLT2 inhibitor, on atrial remodeling in a canine AF model. The study included 12 beagle dogs, with 10 receiving continuous rapid atrial pacing and 2 acting as the nonpacing group. The 10 dogs that received continuous rapid atrial pacing for 3 weeks were subdivided as follows: pacing control group (n=5) and pacing+CAN (3 mg/kg per day) group (n=5). The atrial effective refractory period, conduction velocity, and AF inducibility were evaluated weekly through atrial epicardial wires. After the protocol, atrial tissues were sampled for histological examination. The degree of reactive oxygen species expression was evaluated by dihydroethidium staining. The atrial effective refractory period reduction was smaller (P=0.06) and the degree of conduction velocity decrease was smaller in the pacing+CAN group compared with the pacing control group (P=0.009). The AF inducibility gradually increased in the pacing control group, but such an increase was suppressed in the pacing+CAN group (P=0.011). The pacing control group exhibited interstitial fibrosis and enhanced oxidative stress, which were suppressed in the pacing+CAN group. Conclusions CAN and possibly other SGLT2 inhibitors might be useful for preventing AF and suppressing the promotion of atrial remodeling as an AF substrate. Background Recent clinical trials have demonstrated the possible pleiotropic effects of SGLT2 (sodium–glucose cotransporter 2) inhibitors in clinical cardiovascular diseases. Atrial electrical and structural remodeling is important as an atrial fibrillation (AF) substrate. Methods and Results The present study assessed the effect of canagliflozin (CAN), an SGLT2 inhibitor, on atrial remodeling in a canine AF model. The study included 12 beagle dogs, with 10 receiving continuous rapid atrial pacing and 2 acting as the nonpacing group. The 10 dogs that received continuous rapid atrial pacing for 3 weeks were subdivided as follows: pacing control group (n=5) and pacing+CAN (3 mg/kg per day) group (n=5). The atrial effective refractory period, conduction velocity, and AF inducibility were evaluated weekly through atrial epicardial wires. After the protocol, atrial tissues were sampled for histological examination. The degree of reactive oxygen species expression was evaluated by dihydroethidium staining. The atrial effective refractory period reduction was smaller (P=0.06) and the degree of conduction velocity decrease was smaller in the pacing+CAN group compared with the pacing control group (P=0.009). The AF inducibility gradually increased in the pacing control group, but such an increase was suppressed in the pacing+CAN group (P=0.011). The pacing control group exhibited interstitial fibrosis and enhanced oxidative stress, which were suppressed in the pacing+CAN group. Conclusions CAN and possibly other SGLT2 inhibitors might be useful for preventing AF and suppressing the promotion of atrial remodeling as an AF substrate. Background Recent clinical trials have demonstrated the possible pleiotropic effects of SGLT2 (sodium-glucose cotransporter 2) inhibitors in clinical cardiovascular diseases. Atrial electrical and structural remodeling is important as an atrial fibrillation (AF) substrate. Methods and Results The present study assessed the effect of canagliflozin (CAN), an SGLT2 inhibitor, on atrial remodeling in a canine AF model. The study included 12 beagle dogs, with 10 receiving continuous rapid atrial pacing and 2 acting as the nonpacing group. The 10 dogs that received continuous rapid atrial pacing for 3 weeks were subdivided as follows: pacing control group (n=5) and pacing+CAN (3 mg/kg per day) group (n=5). The atrial effective refractory period, conduction velocity, and AF inducibility were evaluated weekly through atrial epicardial wires. After the protocol, atrial tissues were sampled for histological examination. The degree of reactive oxygen species expression was evaluated by dihydroethidium staining. The atrial effective refractory period reduction was smaller ( =0.06) and the degree of conduction velocity decrease was smaller in the pacing+CAN group compared with the pacing control group ( =0.009). The AF inducibility gradually increased in the pacing control group, but such an increase was suppressed in the pacing+CAN group ( =0.011). The pacing control group exhibited interstitial fibrosis and enhanced oxidative stress, which were suppressed in the pacing+CAN group. Conclusions CAN and possibly other SGLT2 inhibitors might be useful for preventing AF and suppressing the promotion of atrial remodeling as an AF substrate. |
Author | Sakagami, Hiroyuki Kishihara, Jun Fukaya, Hidehira Niwano, Hiroe Hara, Yoshinobu Ishizue, Naruya Ako, Junya Yoshizawa, Tomoharu Nakamura, Hironori Arakawa, Yuki Nishinarita, Ryo Sato, Tetsuro Katsumura, Takafumi Horiguchi, Ai Kobayashi, Shuhei Oikawa, Jun Matsuura, Gen Shirakawa, Yuki Igarashi, Tazuru Satoh, Akira Saito, Daiki Niwano, Shinichi |
AuthorAffiliation | 5 Department of Cardiovascular Medicine Yokohama Asahi Central Hospital Yokohama Japan 3 Department of Cardiovascular Medicine Nerima Hikarigaoka Hospital Nerima Japan 4 Department of Cardiovascular Medicine Yamato Municipal Hospital Yamato Japan 6 Department of Anatomy Kitasato University School of Medicine Sagamihara Japan 1 Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan 2 Department of Education Tamagawa University, College of Education Machida Japan |
AuthorAffiliation_xml | – name: 2 Department of Education Tamagawa University, College of Education Machida Japan – name: 6 Department of Anatomy Kitasato University School of Medicine Sagamihara Japan – name: 1 Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan – name: 5 Department of Cardiovascular Medicine Yokohama Asahi Central Hospital Yokohama Japan – name: 3 Department of Cardiovascular Medicine Nerima Hikarigaoka Hospital Nerima Japan – name: 4 Department of Cardiovascular Medicine Yamato Municipal Hospital Yamato Japan |
Author_xml | – sequence: 1 givenname: Ryo orcidid: 0000-0003-0329-5476 surname: Nishinarita fullname: Nishinarita, Ryo organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan – sequence: 2 givenname: Shinichi surname: Niwano fullname: Niwano, Shinichi organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan – sequence: 3 givenname: Hiroe surname: Niwano fullname: Niwano, Hiroe organization: Department of Education Tamagawa University, College of Education Machida Japan – sequence: 4 givenname: Hironori surname: Nakamura fullname: Nakamura, Hironori organization: Department of Cardiovascular Medicine Nerima Hikarigaoka Hospital Nerima Japan – sequence: 5 givenname: Daiki surname: Saito fullname: Saito, Daiki organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan – sequence: 6 givenname: Tetsuro surname: Sato fullname: Sato, Tetsuro organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan – sequence: 7 givenname: Gen orcidid: 0000-0003-0165-5677 surname: Matsuura fullname: Matsuura, Gen organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan – sequence: 8 givenname: Yuki surname: Arakawa fullname: Arakawa, Yuki organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan – sequence: 9 givenname: Shuhei surname: Kobayashi fullname: Kobayashi, Shuhei organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan – sequence: 10 givenname: Yuki surname: Shirakawa fullname: Shirakawa, Yuki organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan – sequence: 11 givenname: Ai surname: Horiguchi fullname: Horiguchi, Ai organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan – sequence: 12 givenname: Naruya surname: Ishizue fullname: Ishizue, Naruya organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan – sequence: 13 givenname: Tazuru surname: Igarashi fullname: Igarashi, Tazuru organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan – sequence: 14 givenname: Tomoharu surname: Yoshizawa fullname: Yoshizawa, Tomoharu organization: Department of Cardiovascular Medicine Yamato Municipal Hospital Yamato Japan – sequence: 15 givenname: Jun surname: Oikawa fullname: Oikawa, Jun organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan – sequence: 16 givenname: Yoshinobu orcidid: 0000-0001-6339-5116 surname: Hara fullname: Hara, Yoshinobu organization: Department of Anatomy Kitasato University School of Medicine Sagamihara Japan – sequence: 17 givenname: Takafumi surname: Katsumura fullname: Katsumura, Takafumi organization: Department of Anatomy Kitasato University School of Medicine Sagamihara Japan – sequence: 18 givenname: Jun surname: Kishihara fullname: Kishihara, Jun organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan – sequence: 19 givenname: Akira surname: Satoh fullname: Satoh, Akira organization: Department of Cardiovascular Medicine Yokohama Asahi Central Hospital Yokohama Japan – sequence: 20 givenname: Hidehira surname: Fukaya fullname: Fukaya, Hidehira organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan – sequence: 21 givenname: Hiroyuki surname: Sakagami fullname: Sakagami, Hiroyuki organization: Department of Anatomy Kitasato University School of Medicine Sagamihara Japan – sequence: 22 givenname: Junya surname: Ako fullname: Ako, Junya organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33399004$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kc1rVDEUxYNUbDt27U7e0s20eS_fG2EYrG2pKH6sQ15yM6ZkkjF5I-hfb6bTkVYwBHLJPed34Z5TdJRyAoRe9fi873l_cbO4WrRKneNeUEmeoZMBUzFXSuKjR_UxOqv1DrfDB0GYeoGOCSFKYUxP0KelSWYVg4_5d0jdl-1mU6BWqN1iKsHE7jOss4MY0qprfdM1fUhw6F6GsYQYzRRy6j7shC_Rc29ihbOHd4a-Xb77urya3358f71c3M4tG9g0lw47S5jwfhwl9Yr0wozAueHWD5yIJhJgqZDSGTc4odwgKLeOM--pxUBm6HrPddnc6U0Ja1N-6WyCvv_IZaVNmYKNoI1jIKkaxx5TKrmUHBPfUIOwhBowjfV2z9psxzU4C2kqJj6BPu2k8F2v8k8tFGNk6BvgzQOg5B9bqJNeh2qhLSZB3lY9UMGIors7Q68fz_o75BBJE7C9wJZcawGvbZjuF9xGh6h7rHfp6136rVJ6n37zXfzjO6D_5_gDc4axcQ |
CitedBy_id | crossref_primary_10_1097_FJC_0000000000001183 crossref_primary_10_1016_j_biopha_2024_117453 crossref_primary_10_1016_j_intimp_2023_111038 crossref_primary_10_3389_fcvm_2022_902923 crossref_primary_10_1016_j_ijcard_2024_132954 crossref_primary_10_2174_1570161120666211227125033 crossref_primary_10_3390_cells12131796 crossref_primary_10_3390_cimb46090571 crossref_primary_10_4239_wjd_v14_i5_512 crossref_primary_10_1007_s00210_024_03225_1 crossref_primary_10_1152_physiol_00008_2024 crossref_primary_10_1016_j_amjmed_2023_04_035 crossref_primary_10_3390_antiox14030336 crossref_primary_10_1016_j_tcm_2022_04_003 crossref_primary_10_1186_s12933_023_01913_5 crossref_primary_10_1002_jcu_23384 crossref_primary_10_1007_s11010_024_05084_z crossref_primary_10_1111_dom_14854 crossref_primary_10_3390_cells11182915 crossref_primary_10_1016_j_heliyon_2023_e16835 crossref_primary_10_2337_dc22_0714 crossref_primary_10_1111_pace_15038 crossref_primary_10_1111_jce_16554 crossref_primary_10_2459_JCM_0000000000001523 crossref_primary_10_3389_fcvm_2022_903902 crossref_primary_10_3390_jcm13185408 crossref_primary_10_1080_10520295_2023_2262390 crossref_primary_10_3390_ijms23031416 crossref_primary_10_1016_j_jstrokecerebrovasdis_2021_106159 crossref_primary_10_1093_cvr_cvae101 crossref_primary_10_3390_diagnostics11030449 crossref_primary_10_3390_ijms25147711 crossref_primary_10_3390_biomedicines11072085 crossref_primary_10_1007_s40265_021_01565_3 crossref_primary_10_3390_ijms25010535 crossref_primary_10_1016_j_cbi_2024_111229 crossref_primary_10_3390_physiologia3010004 crossref_primary_10_1002_ehf2_13930 crossref_primary_10_3390_antiox13111396 crossref_primary_10_3390_ijms22115937 crossref_primary_10_3390_life13020443 crossref_primary_10_1016_j_jpha_2023_12_007 crossref_primary_10_3389_fcvm_2023_1005408 |
Cites_doi | 10.1161/CIRCULATIONAHA.111.029223 10.2337/dc16-0542 10.1056/NEJMoa1911303 10.1152/ajpheart.00646.2012 10.2337/dc16-0330 10.18637/jss.v082.i13 10.1007/s00380-018-1170-0 10.1093/europace/eus052 10.1530/JOE-17-0457 10.1056/NEJMoa1504720 10.1161/CIRCULATIONAHA.115.017355 10.1056/NEJMoa1812389 10.1136/heartjnl-2012-301952 10.1126/science.1227166 10.1161/01.CIR.104.2.174 10.1016/j.ijcard.2006.04.026 10.1161/CIRCULATIONAHA.115.017545 10.1253/circj.72.318 10.1056/NEJMoa1611925 10.1046/j.1540-8167.2001.00183.x 10.1016/j.bbadis.2015.01.010 10.1016/j.freeradbiomed.2003.07.002 10.1093/cvr/cvx151 10.1007/s00380-016-0874-2 10.1089/ars.2013.5542 10.1111/jdi.13009 10.1161/01.CIR.92.7.1954 |
ContentType | Journal Article |
Copyright | 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. |
Copyright_xml | – notice: 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. |
DBID | AAYXX CITATION NPM 7X8 5PM DOA |
DOI | 10.1161/JAHA.119.017483 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Canagliflozin Suppresses Atrial Remodeling of AF |
EISSN | 2047-9980 |
ExternalDocumentID | oai_doaj_org_article_ad5e849bb10448688603fcd627c34aea PMC7955321 33399004 10_1161_JAHA_119_017483 |
Genre | Journal Article |
GroupedDBID | 0R~ 1OC 24P 53G 5VS 8-1 AAYXX AAZKR ACCMX ACGFO ACXQS ADBBV ADKYN ADZMN AEGXH AENEX AIAGR ALAGY ALMA_UNASSIGNED_HOLDINGS AOIJS AVUZU BAWUL BCNDV CITATION DIK EBS EMOBN GODZA GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 RAH RNS RPM NPM 7X8 AAMMB AEFGJ AGXDD AIDQK AIDYY 5PM WIN |
ID | FETCH-LOGICAL-c525t-8d0dc357ffbb84f9317abe66a6cf26375257ec4788dad2d79d2746cd65ff4c0e3 |
IEDL.DBID | M48 |
ISSN | 2047-9980 |
IngestDate | Wed Aug 27 01:31:41 EDT 2025 Thu Aug 21 18:17:22 EDT 2025 Fri Jul 11 01:14:54 EDT 2025 Thu Apr 03 06:56:18 EDT 2025 Thu Apr 24 22:53:18 EDT 2025 Tue Jul 01 04:01:56 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | atrial remodeling sodium–glucose cotransporter 2 inhibitor atrial fibrillation oxidative stress canagliflozin |
Language | English |
License | This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c525t-8d0dc357ffbb84f9317abe66a6cf26375257ec4788dad2d79d2746cd65ff4c0e3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 For Sources of Funding and Disclosures, see page 11. |
ORCID | 0000-0003-0165-5677 0000-0001-6339-5116 0000-0003-0329-5476 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1161/JAHA.119.017483 |
PMID | 33399004 |
PQID | 2475394394 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_ad5e849bb10448688603fcd627c34aea pubmedcentral_primary_oai_pubmedcentral_nih_gov_7955321 proquest_miscellaneous_2475394394 pubmed_primary_33399004 crossref_citationtrail_10_1161_JAHA_119_017483 crossref_primary_10_1161_JAHA_119_017483 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-01-19 |
PublicationDateYYYYMMDD | 2021-01-19 |
PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-19 day: 19 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Hoboken |
PublicationTitle | Journal of the American Heart Association |
PublicationTitleAlternate | J Am Heart Assoc |
PublicationYear | 2021 |
Publisher | John Wiley and Sons Inc Wiley |
Publisher_xml | – name: John Wiley and Sons Inc – name: Wiley |
References | e_1_3_1_22_2 e_1_3_1_23_2 e_1_3_1_24_2 e_1_3_1_8_2 e_1_3_1_7_2 e_1_3_1_9_2 e_1_3_1_20_2 e_1_3_1_4_2 e_1_3_1_29_2 e_1_3_1_3_2 e_1_3_1_6_2 e_1_3_1_25_2 e_1_3_1_26_2 e_1_3_1_2_2 e_1_3_1_27_2 e_1_3_1_28_2 Kishihara J (e_1_3_1_5_2) 2014; 4 Xie W (e_1_3_1_21_2) 2015; 5 e_1_3_1_13_2 e_1_3_1_12_2 e_1_3_1_11_2 e_1_3_1_30_2 e_1_3_1_10_2 e_1_3_1_17_2 e_1_3_1_16_2 e_1_3_1_15_2 e_1_3_1_14_2 e_1_3_1_19_2 e_1_3_1_18_2 |
References_xml | – ident: e_1_3_1_20_2 doi: 10.1161/CIRCULATIONAHA.111.029223 – ident: e_1_3_1_23_2 doi: 10.2337/dc16-0542 – ident: e_1_3_1_11_2 doi: 10.1056/NEJMoa1911303 – ident: e_1_3_1_25_2 doi: 10.1152/ajpheart.00646.2012 – ident: e_1_3_1_22_2 doi: 10.2337/dc16-0330 – volume: 5 start-page: 1 year: 2015 ident: e_1_3_1_21_2 article-title: Mitochondrial oxidative stress promotes atrial fibrillation publication-title: Sci Rep – ident: e_1_3_1_15_2 doi: 10.18637/jss.v082.i13 – ident: e_1_3_1_7_2 doi: 10.1007/s00380-018-1170-0 – ident: e_1_3_1_6_2 doi: 10.1093/europace/eus052 – ident: e_1_3_1_30_2 doi: 10.1530/JOE-17-0457 – ident: e_1_3_1_10_2 doi: 10.1056/NEJMoa1504720 – ident: e_1_3_1_29_2 doi: 10.1161/CIRCULATIONAHA.115.017355 – ident: e_1_3_1_9_2 doi: 10.1056/NEJMoa1812389 – ident: e_1_3_1_17_2 doi: 10.1136/heartjnl-2012-301952 – ident: e_1_3_1_24_2 doi: 10.1126/science.1227166 – ident: e_1_3_1_2_2 doi: 10.1161/01.CIR.104.2.174 – ident: e_1_3_1_3_2 doi: 10.1016/j.ijcard.2006.04.026 – ident: e_1_3_1_28_2 doi: 10.1161/CIRCULATIONAHA.115.017545 – ident: e_1_3_1_13_2 doi: 10.1253/circj.72.318 – ident: e_1_3_1_8_2 doi: 10.1056/NEJMoa1611925 – ident: e_1_3_1_18_2 doi: 10.1046/j.1540-8167.2001.00183.x – ident: e_1_3_1_26_2 doi: 10.1016/j.bbadis.2015.01.010 – ident: e_1_3_1_16_2 doi: 10.1016/j.freeradbiomed.2003.07.002 – ident: e_1_3_1_14_2 doi: 10.1093/cvr/cvx151 – volume: 4 start-page: 28 year: 2014 ident: e_1_3_1_5_2 article-title: Effect of carvedilol on atrial remodeling in canine model of atrial fibrillation publication-title: Cardiovasc Diagn Ther – ident: e_1_3_1_12_2 doi: 10.1007/s00380-016-0874-2 – ident: e_1_3_1_4_2 doi: 10.1089/ars.2013.5542 – ident: e_1_3_1_27_2 doi: 10.1111/jdi.13009 – ident: e_1_3_1_19_2 doi: 10.1161/01.CIR.92.7.1954 |
SSID | ssj0000627359 |
Score | 2.4347646 |
Snippet | Background Recent clinical trials have demonstrated the possible pleiotropic effects of SGLT2 (sodium-glucose cotransporter 2) inhibitors in clinical... Background Recent clinical trials have demonstrated the possible pleiotropic effects of SGLT2 (sodium–glucose cotransporter 2) inhibitors in clinical... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | e017483 |
SubjectTerms | atrial fibrillation atrial remodeling canagliflozin Original Research oxidative stress sodium–glucose cotransporter 2 inhibitor |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA7iQbyIb-uLCh68VLt5NsdVXBZhRcQFbyVtJrpQuuKuF3-9k7S77IrixVtoEhpmJplvyOQbQs6LVBoOvJMg-qYJFwwSQyFLnKUmnH-W-bfDg3vZH_K7Z_G8UOrL54Q19MCN4K6MFZBxXRQYN_BMZplMmSutpKpk3ECARujzFoKp5gxGtyx0y-WDqObqrtvvYktfognyjC25ocDW_xPE_J4pueB6eptko8WMcbdZ6xZZgXqbrA3aW_Ed8uApBl6qkavGn6M69oU6AyX4JO6GohzxI4SCN-ilYuw3MY7HibPens_6r5qcuNjXRqt2ybB3-3TTT9pKCUkpqJgmmU1tyYRyrigy7jSCAlOAlEaWjkqmPOUplJ4p3xpLrdIWg1GJUhTO8TIFtkdW63ENBySm1F_NGQsKkRJNnZHWGQWgHAKPTgoRuZwJLi9bGnFfzaLKQzghO7mXNLZ03kg6IhfzCW8Ng8bvQ6-9JubDPPV1-IAGkbcGkf9lEBE5m-kxx63i7z9MDeOPSU45xmbaPwWOyH6j1_mvGEOkhgdGRNSSxpfWstxTj14DHbfSQjDaOfyPxR-RdeqTZlLcPPqYrE7fP-AEUc-0OA0G_gWcf_9Q priority: 102 providerName: Directory of Open Access Journals |
Title | Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model |
URI | https://www.ncbi.nlm.nih.gov/pubmed/33399004 https://www.proquest.com/docview/2475394394 https://pubmed.ncbi.nlm.nih.gov/PMC7955321 https://doaj.org/article/ad5e849bb10448688603fcd627c34aea |
Volume | 10 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED-2Dkpfxr7ntise7GEvzmx9Wg-jZGMhFDLGWKBvRrakNmCcLUmh21_fkyxny8he9mYsHbZ1d7o7S_r9AN7UudDMsiLD7JtkjFObaWLLzBmiw_xnqD87PPsspnN2cckvf9MBxQFc7y3tPJ_UfNWObn_8PEeHfx8cXhTvLsbTMV6pEVoXK-l9eIBhSXovncVcv5-WMVJzFeF99sgdwSGlGK_zSNo2BKmA5b8vAf17H-UfgWnyCB7GjDId9ybwGO7Z7gkczuKa-VP44gEIrtqFa5e_Fl3qaTwDYPg6HQfKjvSrDXQ4GMNSbNcp9kfBoXXizwS0_Y651DOntc9gPvn07eM0izwKWcMJ32SlyU1DuXSurkvmFKYMurZCaNE4Iqj0gKi28Tj6RhtipDJYqorGCO4ca3JLn8NBt-zsS0gJ8Qt32liJeRTJnRbGaWmtdJiWFLlNYDQMXNVEkHHPddFWodgQReUHHa9U1Q96Am-3At97fI1_d_3gNbHt5oGxw43l6qqKflZpw23JVF1jmclKUZYipw4_hciGMm11Aq8HPVboSH51RHd2ebOuCMPKTfmDwgm86PW6fdRgFwnIHY3vvMtuS7e4DmDdUnFOSXH835IncET8Ppoc_UmdwsFmdWNfYSK0qc_CD4SzYOZ3WQsHog |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Canagliflozin+Suppresses+Atrial+Remodeling+in+a+Canine+Atrial+Fibrillation+Model&rft.jtitle=Journal+of+the+American+Heart+Association&rft.au=Nishinarita%2C+Ryo&rft.au=Niwano%2C+Shinichi&rft.au=Niwano%2C+Hiroe&rft.au=Nakamura%2C+Hironori&rft.date=2021-01-19&rft.pub=John+Wiley+and+Sons+Inc&rft.eissn=2047-9980&rft.volume=10&rft.issue=2&rft_id=info:doi/10.1161%2FJAHA.119.017483&rft_id=info%3Apmid%2F33399004&rft.externalDocID=PMC7955321 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2047-9980&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2047-9980&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2047-9980&client=summon |